Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodality Therapy With or Without Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer
2024-512502-26-00Phase 2Authorised
- Sponsor
- CRIS Cancer Foundation
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial of durvalumab in muscle-invasive bladder carcinoma (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by CRIS Cancer Foundation. Primary endpoint: Disease-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder carcinoma (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-512502-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512502-26-00.